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Abstract
Pancreatic cysts are increasingly recognized as a dilemma in clinical practice because of their
uncertain risk of malignancy. Because diagnosis by cytology is insensitive, current guidelines suggest
using radiographic and clinical criteria to determine the appropriateness of surgery or surveillance,
although this is far from perfect. Several cyst fluid biomarkers have been reported to aid diagnosis,
and to date, carcinoembryonic antigen is the most accurate in detecting potentially cancerous
mucinous cysts, but not in detecting malignant cysts. Recent studies have highlighted novel cyst fluid
biomarkers based on DNA analysis, protein expression profiling, and secreted proteins that, if
validated, may improve diagnosis and management.
Any physician who has had to tell a patient that they
have pancreatic cancer will appreciate the importance of
proper screening of cysts. Pancreatic cancer, although
fairly rare, is almost invariably fatal once symptomatic.
Pancreatic cysts by contrast are relatively common and, if
small, are generally benign, whereas the surgery to
remove them (pancreatic resection) is major and can
lead to complications and occasionally death. Surgery
carries a much higher risk of mortality in older patients
(particularly those with multiple comorbidities), and if
the premalignant cancer is not actually malignant, often
observation is better than surgery. Therein lies the
dilemma for the clinician and the need for accurate
tools to differentiate between benign, potentially cancer-
ous, and cancerous cysts, which are so far lacking.
In contrast to earlier estimates, it turns out that the
majority of pancreatic cystic lesions are not pseudocysts
(organized collections of fluid around the pancreas) but
neoplastic cystic lesions [1]. There are three major types
of cyst: serous cystadenoma (SCA), mucinous cystic
neoplasm (MCN), and intraductal papillary mucinous
neoplasm (IPMN). Pseudocysts and SCA lesions are
nonmucinous and lack malignant potential. MCN and
IPMN lesions are mucinous cysts with recognized
potential to become pancreatic cancer. Once a cyst is
identified, the clinician must determine whether it is a
mucinous cyst and, if so, whether it is malignant.
Because there is no accepted safe and reliable technique
to acquire pancreatic tissue without surgery, consensus
guidelines were created to identify patients at risk who
require surgery [2]. They recommend surgical resection
for suspected IPMN lesions with main duct involvement
and MCN lesions in surgically fit patients. IPMN lesions
with branch duct involvement can be observed if (a) the
cyst size is less than 3 cm, (b) there is absence of an
intracystic mural nodule, (c) the patient is asympto-
matic, (d) the main pancreatic duct is less than 6 mm
wide, and (e) cyst fluid cytology is negative for cancer.
Based on available data, the guidelines employ imaging
and clinical characteristics to discriminate between the
types of cystic lesions. While subsequent validation
studies generally support these recommendations, there
are instances where the guidelines are suboptimal [3-7].
For example, in one tertiary medical center, preoperative
diagnosis in one-third of their surgical cases was
incorrect [8]. Imaging has limited diagnostic accuracy
(~40%) because the different types of cysts have
substantially overlapping radiographic features [9]. The
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because the fluid is relatively acellular [10,11]. Given this
state of affairs, cyst fluid biomarker discovery is appeal-
ing because it is easy to obtain with endoscopic
ultrasound. Also, cyst fluid has the advantage in that it
appears to be relatively isolated from serum so,
theoretically at least, it contains only secreted biological
material from the epithelial cyst lining. To date, several
tests using cyst fluid to diagnose premalignant cysts are
in use. These include cytology, tumor markers (i.e.,
carcinoembryonic antigen [CEA], carbohydrate antigen
[CA] 19-9, and CA 72-4), biochemical markers (i.e.,
amylase), cyst fluid viscosity, and various stains (i.e., the
periodic acid–Schiff staining method and mucin)
[12,13]. Among these options, the tumor marker CEA
has the highest diagnostic accuracy of 79% (sensitivity
73%, specificity 84%) for discriminating premalignant
mucinous cysts from nonmucinous cysts [10]. CEA,
however, cannot differentiate a benign premalignant cyst
from a malignant cyst. This matters in the clinic because
current evidence suggests the natural history of progres-
sion to malignancy is slow [14]. Because of this and the
associated morbidity of pancreatic resection, surgery is
not recommended for all premalignant cysts, and this is
particularly true in the elderly.
Understandably, therefore, there has been much interest in
several recent studies on novel cyst fluid-based biomarkers
(DNAornovelproteins;seeTable1).Thelargeststudy[11]
was a multicenter prospective study that evaluated the
usefulness of DNA analysis in cyst fluid, obtained using
endoscopic ultrasound. The quality and quantity of DNA,
the presence of a K-ras mutation, and the mean allelic loss
amplitude (a relative measure of the proportion of DNA in
a cell with hemizygous loss) could accurately differentiate
benign nonmucinous from potentially cancerous muci-
nous cysts among 113 patients with a histological diag-
nosis. The presence of K-ras mutations alone had a
sensitivity of 45% and specificity of 96%. Adding this to
CEA increased the sensitivity for mucinous cysts from
64% to 82% without compromising specificity. While the
presence of a K-ras mutation did not differentiate benign
mucinouscystsfrommalignantcysts,otheraspectsofDNA
analysis appeared to independently predict malignant
cysts.Aretrospectivestudyfoundthattheconcordancerate
between cyst fluid CEA and DNA in predicting mucinous
cysts among 83 patients was poor [15], although in the 19
patients with histological data, CEA was more accurate. If
CEA and DNA analysis were combined, however, the
diagnostic accuracy was perfect for this small sample.
Besides DNA-based markers, differential secretion of
proteins into the cyst fluid can also identify mucinous
cysts. One group evaluated whether differences in
expression levels of 54 proteins associated with pancrea-
tic cancer might exist between nonmucinous and
mucinous cysts [16]. Cyst fluid with histological correla-
tion was obtained from 15 patients with SCA, 12 patients
with noninvasive MCN, and 32 patients with noninva-
sive IPMN. Comparing SCA and IPMN cystic lesions, 34
proteins were differentially expressed, whereas compar-
ing SCA and MCN cystic lesions, 13 proteins were
differentially expressed. Based on this, the investigators
constructed a classification system capable of differen-
tiating SCA and IPMN cystic lesions with 92% accuracy.
Another study evaluated the presence of mucin 1 (MUC1),
MUC5AC, MUC16, and their glycan variants among
nonmucinous and mucinous cysts [17]. Using a high-
throughput antibody microarray of 53 cyst fluid samples
with histology, differences in protein expression and
glycosylation variants were identified. Specifically, the
wheat germ agglutinin detection of MUC5AC was sig-
nificantly upregulated among mucinous cysts. In combi-
nation with CA 19-9, these two biomarkers provided a
sensitivity of 87% and specificity of 86% for detection of
potentially cancerous mucinous cysts.
Differentiating nonmucinous from mucinous cysts is
useful but biomarkers that identify malignant mucinous
cysts are needed. One small study suggests that Plectin-1
(Plec-1), a marker associated with pancreatic cancer, may
be a candidate [18]. Using cyst fluid from seven patients
with an established diagnosis of IPMN, Plec-1 was
detected in all four malignant cysts and none of the three
benign cysts.
These studies highlight the potential for cyst fluid
biomarkers to improve the diagnosis of pancreatic
cystic lesions. While encouraging, the current studies
are limited in their design: the relatively small sample
sizes and the selection bias in using surgical samples
(i.e., cysts from patients selected for surgery may differ
from those not selected for surgery), may overstate the
true diagnostic accuracy of a candidate biomarker.
Further testing and validation is needed to demon-
strate that these candidate biomarkers significantly
improve upon CEA, and should be incorporated into
clinical practice.
Despite these limitations, there are reasons for opti-
mism. First, these studies demonstrate that there are
numerous potential biomarkers (both DNA and protein
material) in the cyst fluid that are differentially
expressed among cyst types. Their varying expression
levels may in the near future accurately differentiate
between not just nonmucinous and mucinous cysts, but
also premalignant and malignant cysts. Second, these
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analysis is minute (6400 microliters) and easily obtain-
able by endoscopic ultrasound even from cysts less than
1 cm in diameter.
While we wait for these developments, what can cyst
fluid analysis tell the clinician about a pancreatic cyst
today? It is currently poor at diagnosing cancer, but is
fairly accurate at picking out the mucinous cysts with
malignant potential. When combined with other features
such as an intracystic nodule, associated symptoms
(including pancreatitis, pancreatic-type pain, or jaun-
dice), and a large cyst size (generally considered greater
than 3 cm), it can help identify which premalignant cysts
are at a relatively higher risk of malignant transforma-
tion. Patients with these features, if surgically fit, should
be strongly considered for surgery. In the absence of
these features, mucinous cysts can be monitored with a
small risk of cancer progression.
Hopefully we will not have to wait too long for cyst fluid
biomarkers that can predict the malignant transforma-
tion of premalignant cysts to reach the clinic.
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